Publications by authors named "Emmanuelle Herlem"
Aims: Sweet's syndrome is an acute febrile neutrophilic dermatosis first described in 1964 by Robert Douglas Sweet. The pathophysiological mechanism is not fully established; however, several cases of Sweet's syndrome have been reported following drug administration.
Methods: To investigate the existence of pharmacovigilance signals between drugs and the occurrence of Sweet's syndrome, we performed a case/non-case study on reports of 'acute febrile neutrophilic dermatosis' registered in the French pharmacovigilance database.
Article Synopsis
- Community pharmacists (CPs) have historically had limited access to patients' eGFR, but recent improvements in electronic health records are increasing their access to this critical information.
- A study involving 70 CPs over six months found that they were able to identify 99 drug-related problems (DRPs) in elderly patients with renal impairment, compared to 184 identified by expert pharmacists.
- The findings indicate that while CPs can effectively detect DRPs, expert pharmacists are more successful, highlighting the need for improved training and support for CPs in managing complex medication issues for this patient population.
Introduction: Angiotensin-converting enzyme inhibitors (ACEIs) can induce or aggravate psoriasis. This risk is not specified in the Summary of Product Characteristics (SmPC) of some drugs of this class, such as captopril or enalapril. We aimed to investigate the association between psoriasis and ACEI exposure.
View Article and Find Full Text PDFIntroduction: Methylphenidate is a piperidine derivative structurally and pharmacologically similar to amphetamine. Methylphenidate is indicated for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 years of age and over when remedial measures alone prove insufficient. In adults, its indication, except in narcolepsy, is not defined.
View Article and Find Full Text PDFBackground: Depressive disorders and use of antidepressants are associated with adverse effects on sexual function. In pharmacoepidemiological studies, sexual disorders are reported by more than 50 % of patients taking serotonin reuptake inhibitors (SRIs).
Objective: The aim of this study was to determine the reporting rate of sexual disorders in association with SRIs, and to investigate the association between reported cases and the use of SRIs.
Background: Hyperprolactinaemia is a common endocrinological disorder that can be caused by a variety of physiological and pathological conditions, although in a large proportion of cases hyperprolactinaemia is drug-induced. Serotonin reuptake inhibitors (SRIs) are reportedly associated with hyperprolactinaemia; however, the number of published cases in the literature is limited.
Objective: The aim of the study was to investigate the association between exposure to SRIs and the risk of reporting of hyperprolactinaemia in a spontaneous reporting database.
Through a review of both the cases in the national pharmacovigilance database and the literature, we evaluated the importance of propofol-induced hallucinations and dreams which are not mentioned in the propofol Summaries of Product Characteristics (SPC). Postoperative hallucinations occurring in patients anaesthetized by propofol is not exceptional even with low doses of propofol. Most of the hallucinations are described as pleasant with a frequent "sexual connotation", uninhibited behavior or a verbal expression of patient's intimate thoughts.
View Article and Find Full Text PDF